Revenue rose 20.7% but PBT swung to a $1.6m loss despite margin gains

The headline NPAT improvement of +92.0% (loss narrowed from -$2.5m to -$0.2m) is the wrong read because the effective tax rate moved sharply — from 377.8% in FY23 to 87.5% in FY24 — so PBT is the cleaner operating measure and it deteriorated.

Operating cash flow rose to $11.7m from $6.5m and pre-lease FCF reached $5.1m, materially above Annolyse's historical baseline of -$0.4m and the prior-period range of -$5.1m to $2.9m. Despite this, year-end cash fell to $5.6m from $12.7m as $6.6m of capex and a $5.7m gross-borrowings reduction absorbed the inflow. Receivable days expanded from 20.8 to 67.9 (+47.1 days) while inventory days eased modestly.

Revenue grew 20.7% and gross margin lifted 304bps, but operating profit went negative. Cost growth below the gross-profit line (overheads, R&D, biological-asset accounting, or other operating items) outpaced the gross-profit dollars added. This matters because the company is presenting the year as record sales and ahead-of-guidance Adjusted US GAAP EBITDA, yet the audited operating profit moved the other way.

Receivables absorbed material cash. Operating working capital rose by $19.3m, with the trade-debtor movement swinging from a $3.2m release in FY23 to a $12.6m absorption in FY24, and receivable days more than tripling. Whether this reflects late-cycle pricing on Q4 deliveries, a customer concentration in slower-paying buyers, or a permanent shift in terms is the most important question for next-year cash flow.

Cash position halved despite stronger OCF. Cash fell from $12.7m to $5.6m as the company prioritised debt reduction ($5.7m of gross borrowings repaid) and stepped up capex 17.9% to $6.6m (9.7% of revenue). Net debt nonetheless edged up slightly to $14.4m from $13.0m because cash fell faster than debt did. Liquidity is thinner heading into FY25.

The half-year context is consistent with this being a heavily second-half weighted business: HY24 carried only 19.5% of full-year revenue ($13.2m of $67.7m) and 50% of NPAT loss. The implied 2H revenue of $54.5m is therefore the operative shape for understanding next year, not a smoothed run-rate. The release does not support claims about FY25 momentum because no forward-work or order-book data is disclosed.

PBT moving from +$0.9m to -$1.6m is the structural read, and it is negative.

The cash quality is mixed. Pre-lease FCF of $5.1m sits above Annolyse's historical baseline (mean -$0.4m), which is genuinely better than the recent run. However, OCF of $11.7m is achieved alongside $19.3m of working capital absorption — meaning underlying cash generation before working capital is large, but a meaningful portion of FY24 revenue has not yet been collected. If receivable days normalise back toward the FY23 level, FY25 OCF would benefit; if 67.9 days is the new run-rate, the working-capital base has stepped up permanently and consumed $7m–$8m of cash one-time.

• Capex intensity at 9.7% of revenue is roughly flat versus 9.8% prior, so the cash drain is volume-driven, not investment-step-up.
• No dividend was declared, consistent with prior period.

This briefing cannot assess the FY25 outlook, the Adjusted US GAAP EBITDA bridge, or segment-level profitability for US South and Brazil because those disclosures are not included in the supplied release data.